Myriad Genetics, Inc. announced that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk®? Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer.
The study, "Ass Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management", was first shared at the 2024 ASCO®? Annual Meeting. Key findings include: RiskScore predicted a different risk level than Tyrer-Cuzick for nearly 20% of patients; Patients with a 20% lifetime risk of breast cancer predicted by RiskScore were significantly more likely to have guidelines-aligned screening, such as mammography, breast MRI, and genetic counseling compared to those with.
